Literature DB >> 27612005

A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis.

Nicolas Girerd1, João Pedro Ferreira1,2, Patrick Rossignol1, Faiez Zannad1.   

Abstract

Keywords:  BNP stratum; Heart failure; Randomized evidence; Spironolactone; TOPCAT trial; interaction

Mesh：

Substances：

Year:  2016        PMID： 27612005     DOI： 10.1002/ejhf.621

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN： 1388-9842            Impact factor:   15.534


× No keyword cloud information.
  10 in total

1.  Heart failure with mid-range ejection fraction and with preserved ejection fraction.

Authors:  J Petutschnigg; F Edelmann
Journal:  Herz       Date:  2018-08       Impact factor: 1.443

2.  New Insights into Medical Therapy for Heart Failure with Preserved Ejection Fraction.

Authors:  Eduardo Thadeu de Oliveira Correia; Evandro Tinoco Mesquita
Journal:  Arq Bras Cardiol       Date:  2022-09-12       Impact factor: 2.667

3.  Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure.

Authors:  Julio A Chirinos; Lei Zhao; Yi Jia; Cecilia Frej; Luigi Adamo; Douglas Mann; Swapnil V Shewale; John S Millar; Daniel J Rader; Benjamin French; Jeff Brandimarto; Kenneth B Margulies; John S Parks; Zhaoqing Wang; Dietmar A Seiffert; James Fang; Nancy Sweitzer; Christina Chistoffersen; Björn Dahlbäck; Bruce D Car; David A Gordon; Thomas P Cappola; Ali Javaheri
Journal:  Circulation       Date:  2020-04-02       Impact factor: 29.690

4.  Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

Authors:  Nicole Martin; Karthick Manoharan; Ceri Davies; R Thomas Lumbers
Journal:  Cochrane Database Syst Rev       Date:  2021-05-22

Review 5.  Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

Authors:  Nicole Martin; Karthick Manoharan; James Thomas; Ceri Davies; R Thomas Lumbers
Journal:  Cochrane Database Syst Rev       Date:  2018-06-28

Review 6.  Heart failure with mid-range or mildly reduced ejection fraction.

Authors:  Gianluigi Savarese; Davide Stolfo; Gianfranco Sinagra; Lars H Lund
Journal:  Nat Rev Cardiol       Date:  2021-09-06       Impact factor: 32.419

Review 7.  Practical outpatient management of worsening chronic heart failure.

Authors:  Nicolas Girerd; Nathan Mewton; Jean-Michel Tartière; Damien Guijarro; Patrick Jourdain; Thibaud Damy; Nicolas Lamblin; Antoni Bayes-Génis; Pierpaolo Pellicori; James L Januzzi; Patrick Rossignol; François Roubille
Journal:  Eur J Heart Fail       Date:  2022-04-27       Impact factor: 17.349

Review 8.  Targeting Myocardial Fibrosis-A Magic Pill in Cardiovascular Medicine?

Authors:  Alina Scridon; Alkora Ioana Balan
Journal:  Pharmaceutics       Date:  2022-07-30       Impact factor: 6.525

9.  Spironolactone use is associated with improved outcomes in heart failure with mid-range ejection fraction.

Authors:  Nobuyuki Enzan; Shouji Matsushima; Tomomi Ide; Hidetaka Kaku; Taiki Higo; Miyuki Tsuchihashi-Makaya; Hiroyuki Tsutsui
Journal:  ESC Heart Fail       Date:  2020-01-17

Review 10.  Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?

Authors:  Mark Sweeney; Ben Corden; Stuart A Cook
Journal:  EMBO Mol Med       Date:  2020-09-21       Impact factor: 12.137
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.